Navigation Links
Simbionix Announces Initiation of the REHEARSAAAL Study

CLEVELAND, October 24, 2013 /PRNewswire/ --

Simbionix, a leading provider of innovative training solutions, announced the initiation of the REHEARSAAAL study which evaluates the clinical benefits of preoperative patient specific simulation using the PROcedure Rehearsal Studio™ for the treatment of Abdominal Aortic Aneurysms (AAAs) by Endovascular Aortic Repair (EVAR). This study will be conducted by multidisciplinary group of physicians from vascular surgery, interventional radiology and cardiology departments in hospitals across the United States and Europe.


PROcedure Rehearsal Studio allows physicians to create a 3D anatomical model based on a patient's individualized CT scan to simulate, analyze and evaluate preoperative surgical options. The availability of patient specific technology allows the interventional team to engage in simulated practice procedures utilizing a patient's own anatomy prior to performing an actual procedure, potentially leading to more precise treatment decisions, a reduction of errors, improved outcomes, and enhanced operator confidence.  Prior case simulation may allow patients to have a shortened procedure with less time under sedation, a reduction in radiation exposure, and a decrease in procedural complications.

This two-arm study will randomize 150 patients in 1:1 ratio, stratified by operator's experience and procedure complexity. It compares real EVAR procedure parameters with an emphasis on radiation exposure time and safety parameters. Physicians treating patients enrolled for the preoperative patient specific simulation group will go through the simulated experience - a virtual practice session - prior to performing the real case.  Outcomes in these patients will be compared to procedures performed without prior simulated practice as is routinely done.

Dr. John Rundback, Medical Director, Interventional Institute at Holy Name Medical Center and the study's Principal Investigator, "Simulation has proven experience in the aviation and other industries in improving performance and reducing errors. The Simbionix PROcedure Rehearsal Studio provides a platform to practice and optimize procedures using personalized patient data in advance of performing live cases, assuring an unparalleled opportunity to streamline all aspects of the actual procedure, improve patient safety, and reduce the use of additional costly devices that are often needed when procedures are unable to be rehearsed."

See the PROcedure Rehearsal Studio at TCT in booth # 2408 and at VEITH in booth # 110.

About Simbionix:

Simbionix is committed to delivering quality products, advancing clinical performance and optimizing procedural outcomes.

Rebecca Levy, Marketing Communications Manager,; +1-216-229-2070#128

SOURCE Simbionix Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Após o sucesso do lançamento nos Estados Unidos, o novo U/S Mentor da Simbionix será introduzido pela primeira vez na Europa
2. Inflamax Research, Inc. Announces Fully-Integrated Clinical e-Source Data Management Services
3. The Comfort Outlet Announces No Shipping Costs on All Outlast Mattress Pads
4. Brainwave Signal Interpretation Software Company EyeMynd Announces Move to Silicon Valley
5. The Conference Forum Announces the Launch of the 2nd Annual Medicaid Rebate Summit
6. Genufood Energy Enzymes Corp. Announces $20 Million Equity Purchase Agreement
7. Elan Wellness Center Announces Theralase Therapeutic Laser Treatment is Now Available
8. Jeeven BioSciences, Inc. Announces the Release of Its Neuro-XTM Serum-Free and Xeno-Free Tissue Culture Media
9. Spartan Bioscience Announces Medical Device Registration of Rapid CYP2C19 Testing System in Saudi Arabia
10. TM&S, LLC Announces Representation of ecoMIM
11. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
Post Your Comments:
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
Breaking Biology News(10 mins):